Please use this identifier to cite or link to this item:
|Title:||Landmark Pharma Patent Jurisprudence in India|
|Authors:||Nair, Gopakumar G|
|Keywords:||Gleevec;Section 3(d);Supreme Court order;IPAB;Erlotinib;Sitagliptin;Sorafenib;Dasatinib;Sunitinib;Date of patent|
|Abstract:||In a short span of less than 10 years after the new WTO/TRIPS based product patent regime came into effect, there have been many landmark judgments from Indian Courts on interpretation of various provisions of the exhaustive (Indian) Patents Act, 1970, as amended. Even though very large number of product patents have been granted during this period, patent challenges and infringement suits are limited to a few blockbuster molecules. Currently, litigations are in progress, including those in appeals as well as on matters remanded back to patent office. The landmark cases, in recent times, are dealt with, herein. Additional areas which may require judicial intervention arising out of the ambiguities in the Act and Rules are also briefly dealt with.|
|ISSN:||0975-1076 (Online); 0971-7544 (Print)|
|Appears in Collections:||JIPR Vol.19(2) [March 2014]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.